CHUC Charlie's Holdings, Inc.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1134765 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY266.1%
TTM net income YoY-222.5%
TTM EPS YoY-171.4%
Revenue 3-yr CAGR9.2%
Net income 3-yr CAGR—
Margins
Gross margin27.4%
Operating margin-10.8%
Net margin-7.9%
FCF margin—
EBITDA margin-10.7%
Returns
ROE-73.5%
ROA-20.9%
ROIC (approx.)-126.2%
Asset turnover2.63x
Leverage & solvency
Liabilities / assets75.5%
Debt / equity0.00x
Current ratio1.65x
Interest coverage-9.86x
Cash quality & payout
Operating cash flow / net income2.15x
Accruals ratio23.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $20.92M | $7.76M |
| Cost of revenue | $15.26M | $4.89M |
| Gross profit | $5.66M | $2.88M |
| SG&A expense | $6.37M | $5.61M |
| Operating income | -$2.17M | -$3.30M |
| Interest expense | $692,000 | $703,000 |
| Pretax income | $4.59M | -$4.00M |
| Income tax | $275,000 | $0 |
| Net income | $4.50M | -$4.16M |
| EBITDA | -$2.13M | -$3.20M |
| EPS (basic) | 0.02 | -0.02 |
| EPS (diluted) | 0.02 | -0.02 |
| Weighted avg. shares (diluted) | 278.54M | 234.80M |
| Balance sheet | ||
| Cash & equivalents | $1.32M | $211,000 |
| Receivables | $440,000 | $331,000 |
| Inventory | $6.72M | $2.13M |
| Current assets | $10.77M | $3.72M |
| PP&E, net | $37,000 | $53,000 |
| Total assets | $11.56M | $3.94M |
| Current liabilities | $7.63M | $5.58M |
| Long-term debt | — | $2.16M |
| Total debt | — | $2.16M |
| Total liabilities | $8.14M | $5.72M |
| Shareholders' equity | $3.42M | -$1.78M |
| Net debt | — | $1.95M |
| Shares outstanding | 270.65M | 257.29M |
| Cash flow statement | ||
| Operating cash flow | -$5.78M | -$1.62M |
| Capital expenditure | $23,000 | $0 |
| Free cash flow | -$5.80M | -$1.62M |
| Investing cash flow | $7.48M | $0 |
| Financing cash flow | -$590,000 | $1.47M |
| Depreciation & amortization | $39,000 | $102,000 |
| Stock-based compensation | $186,000 | $230,000 |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.